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Before the use of highly active antiretroviral therapy 
( H M T ) ,  disseminated Mycobarterium avium complex 
(DMAC) infection was a common opportunistic in- 
fection in adults infected by HIV [l-31. The incidence 
of this disease increased in the later stage of HIV 
infection, occurring in 15-24% of cases [2,4]. Previous 
studies had shown that DMAC infection was associated 
with shorter survival and that antimycobacterial 
treatment improved survival [5-81. However, mortality 
was still high, due to the deep underlying immuno- 
deficiency and because diagnosis is reached after a long 
period of silent mycobacterial replication, a pheno- 
menon emphasized by the time (3-4 weeks) required 
for diagnosis through conventional cultures. Finally, 
antimycobacterial treatment is often started late, which 
is prejudicial for patients already severely ill [6]. 
Such reasons support the concept of prophylaxis with 
rifabutin [4], clarithromycin [9], azithromycin or a 
combination of azithromycin and rifabutin [lo] in 
patients presenting an advanced immune deficiency 
(lower than 100/mm3). However, clarithromycin mono- 
therapy may select resistant Mycobacteriurn avium com- 
plex (MAC) [7], and the large number of drugs 
required by the immune condition at this stage of the 
disease may affect compliance with prophylaxis. 
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We conducted a prospective observational study in 
HIV-infected patients whose CD4 cell counts were 
< 100/mm3, to determine the characteristics, present at 
the time of DMAC diagnosis, associated with shorter 
or longer survival, in order to identi6 the more severely 
ill patients who need the most effective antimyco- 
bacterial treatment. 
PATIENTS AND METHODS 
Our report includes all HIV-infected patients with a 
CD4 count <100/mm3 who had newly diagnosed 
DMAC by blood or bone marrow culture. From 
January 1993 to September 1995, 288 patients had 
CD4 lymphocyte counts regularly <100/mm3. All 
patients received during the study period various 
combinations of antiretroviral drugs, which did not 
include at this time HIV protease inhibitors. Since 
November 1993, we proposed to a l l  our patients that 
they should receive systematic rifabutin (300 mg/day) 
and continue the follow-up. 
At the date of DMAC infection, information 
about age, sex, risk factors for HIV infection, CD4 
count, unexplained fever 238.5"C for more than 2 
weeks and a rapid unexplained cachexia defined by a 
weight loss of 25% occurring over a period of 2 
months was obtained. We did not take into account the 
occurrence of night sweats and diarrhea, which are 
both often associated with DMAC infection, but which 
are not easy to quantie. Previous rifabutin prophylaxis 
and the time to DMAC diagnosis, prior AIDS-defining 
illness, prior antiretroviral therapy, time to the first 
AIDS-defining event and DMAC, and the onset of an 
AIDS-associated event occurring during the same 
period or in the month following the positive culture, 
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were also taken into account. At the time of DMAC 
diagnosis, biological parameters such as hemoglobin 
concentration, lymphocyte and platelet counts and 
levels of alanine aminotransferase (ALAT), aspartate 
aminotransferase (ASAT), alkaline phosphatases and y- 
glutamyltransferase were also noted. Severe anemia was 
defined as a hemoglobin level <9 g/dL, thrombopenia 
as a count <100000/mm3, and severe lymphopenia as 
a count <400/mm3. Cholestasis was defined by levels 
of alkaline phosphatase and y-glutamyltransferase 
higher than twice the normal values, and cytolysis by 
ALAT and ASAT levels higher than twice the normal 
values. 
Follow-up began when DMAC was diagnosed, 
and continued until a patient died, or was lost to 
follow-up, or the end on the study on 31 December 
1995. 
DMAC infection was defined by the isolation of 
MAC from a single blood or bone marrow specimen. 
To recover MAC, 10 mL of blood was transferred 
aseptically into an Isolator tube, using the lysis- 
centrifugation method (Wanpole Lab, Cranbury, NJ, 
USA), and culture was performed on Lowenstein- 
Jensen solid medium. For bone marrow specimens, 
culture was performed dn-ectly on Lowenstein-Jensen 
solid medium. All cultures were incubated for 8 weeks 
to detect the growth of any mycobacteria. For our 
HIV-positive cohort with CD4 count <100/mm3, 
blood cultures were performed every 2 months in cases 
of patients free of symptoms suggesting a DMAC infec- 
tion. They were performed more frequently, as were 
cultures of bone marrow specimens, when considered 
necessary in symptomatic patients. 
Statistical analysis 
Survival analysis was done using the Kaplan-Meier 
method with regard to various parameters. Groups 
were compared by the Mantel-Cox method. Each 
parameter found to be correlated to survival by uni- 
variate analysis @<0.10) was included in a stepwise 
logistic regression (Cox model) using BMDP statistical 
software (Los Angeles, California, USA), since the 
hazards of the variables selected for the multivariate 
analysis were proportional over time, in order to 
determine the relative effect of such factors on survival. 
RESULTS 
Between January 1993 and September 1995, 52 
patients had a DMAC infection microbiologically 
defined, among 288 patients with a CD4 count 
<100/mm3, leading to a cumulative incidence of 18%. 
Twenty-three cases were diagnosed during the first year 
of the study, 15 during the second, and 14 until 
September 1995, with no other case after then. Thus, 
the annual incidence was 8% (23/288) in the first year, 
5.2% in the second and 4.9% in the third. Rifabutin 
prophylaxis was given to 119 subjects with CD4 cell 
counts <100/mm3 (41.3%) in 1994 and to 150 (52.1%) 
in 1995. 
Among the 288 HIV-infected patients with a CD4 
count <100/mm3, mean age was 35 years (24-67), 78% 
were male and 71% were homosexuals. The mean CD4 
count was 3 9 / m 3  (range 2-100). Among the 52 
patients with DMAC infection, mean age was 37 years 
(26-65), 85% were male and 67% were homosexuals. 
Mean CD4 count was 10/mm3 (0-70). None of these 
hfferences was statistically significant. AU patients with 
DMAC infection were Caucasian, except for one. The 
baseline characteristics of these 52 patients are shown 
in Table 1. All the 52 patients had at least one blood 
culture (BC) performed, and 10 a bone marrow (BM) 
specimen taken at the date of DMAC diagnosis. 
Table 1 
patients with CD4 counts <100/mm3 and Dh4AC 
Characteristic Number of cases (%) 
Baseline characteristics of 52 HIV-infected 
Sex 
Male 
Female 
Mean age (years) (range) 
HIV risk 
Homosexual 
Intravenous drug user 
Heterosexual 
Others" 
Prior AIDS-defining illness 
Mean time between AIDS and DMAC 
diagnosis (months) (range) 
Prior rifabutin prophylaxis 
Prior antiretroviral therapy 
AIDS-associated eventb 
CMV-associated eventb 
CD4 cell count /mm3 (range) 
Mean 
Median 
Fever 
Weight loss' 
Severe anemiad 
Severe lymphopenia' 
Thrombopenia 
Cholestasisg 
44 (84) 
37 (26-65) 
8 (16) 
34 (65) 
9 (17) 
3 (6) 
6 (12) 
37 (71) 
17.5 (0-75) 
22 (42) 
40 (77) 
28 (54) 
11 (21) 
10 (0-70) 
4 
42 (81) 
29 (56) 
22 (42) 
34 (65) 
12 (23) 
22 (42) 
"Bisexual, transfusion. 'AIDS-associated event at the time of 
DMAC diagnosis or in the following month. 'Weight loss 25% in 
2 months. dHemoglobin level <9 g/dL. 'Total lymphocytes count 
<400/mm3. fPlatelet count <lo0 OOO/mm3.. gAlkaLine phosphatases 
and y-glutamyltransferase 2 2  X upper limit of normal. 
CMV, cytomegalovirus. 
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DMAC infection was diagnosed by BC in 49 patients 
(94%) and by BM in three while BCs performed at the 
same time were negative. BCs and BM specimens were 
both positive for MAC in two patients. 
At the time of DMAC infection diagnosis, 37 
patients (7 1%) had developed a previous AIDS-defining 
illness (30 an opportunistic infection, five a Kaposi’s 
sarcoma and two a non-Hodgkin’s lymphoma). Equdy, 
at the time of diagnosis and during the month 
following the diagnosis, 28 patients (54%) had at least 
another AIDS-related event. In 21 patients, one or 
more new opportunistic infections occurred (two pneu- 
mocystosis, five cerebral toxoplasmosis, two Candida 
albirans esophagitis, seven cryptosporidiosis, 11 cyto- 
megalovirus (CMV) infection, including three retinitis, 
six colitis and two meningoencephalitis). Two patients 
developed a lymphoma at the time of DMAC diag- 
nosis, while two others experienced a relapse of a 
previous diagnosed lymphoma. Five others developed 
a visceral Kaposi’s sarcoma requiring cytostatic 
chemotherapy. 
A fever lasting for more than 2 weeks was noted in 
42 patients (81%), while weight loss was noted in 29 
(56%). Both symptoms were associated in 24 patients. 
Four patients (8%) were clinically asymptomatic at time 
of positive culture. Severe anemia was noted in 22 
patients, severe lymphopenia in 34, and thrombopenia 
in 12. Cholestasis was noted in 22 patients, and cytolysis 
in 6. Finally, the liver parameters were strictly normal 
in 21 patients, and showed insignificant changes in 
three. 
Rifabutin prophylaxis was given to 22 patients 
(42%) for a mean period of 6.7 months (from 1 to 21). 
Eight patients had received this prophylaxis for less than 
3 months while six developed DMAC infection after 1 
year of prophylaxis. Considering the three patients 
whose diagnosis was made according to BM biopsies 
while blood cultures remained negative, only one of 
them previously received prophylaxis for 1 month. In 
1993, one of 23 DMAC infections appeared under 
rifabutin prophylaxis, in 1994, 12 of 15 and in 1995, 
nine of 14. 
Antimycobacterial treatment was given to 42 
patients (85%). Ten patients &d not receive any treat- 
ment, since they died before MAC was identified. A 
combination of clarithromycin, rifabutin and etham- 
butol was given to 17 patients. In the other cases, 
treatment consisted of a combination of at least two of 
clarithromycin, rifabutin, ethambutol, ciprofloxacin or 
clofazimin. Finally, five patients received bitherapy, 29 
tritherapy, and eight quadritherapy. 
During the follow-up and at the date of evaluation 
(December 1995), 45 patients (87%) with DMAC 
infection died. Their median survival after diagnosis 
was 4 months (0-20). Twenty-two patients survived for 
less than 3 months (42%), while eight were still alive 1 
year later (15%). Among early deaths (less than 3 
months), an AIDS-associated event was noted in 15 
(68%). In this group, the mean number of events was 
1.7/patient (from 1 to 3). In contrast, only two patients 
in the group who survived for more than 1 year 
experienced an AIDS-associated event (0.25/patient: 
0-1). Finally, 22 patients survived for between 3 and 12 
months. In this intermehate group, 11 (50%) had one 
or two AIDS-associated events (mean: lS/patient). In 
December 1995, seven patients were alive, with a 
median survival of 7 months (range 4-22). Among 
twenty-two patients who received rifabutin prophy- 
laxis, 18 died during the study period (82%) after a 
median survival of 2 months (0-20). Ten died in less 
than 3 months (45%), while one is still alive 1 year later. 
Tables 2 and 3 summarize the univariate and 
multivariate relationship between some parameters and 
survival. In the univariate analysis, no correlation 
between the past record of AIDS-defining illness and 
survival was found, even if the time between the date 
of the first AIDS event and DMAC diagnosis was taken 
into account. Similarly, no correlation was found 
between survival and some other variables: sex, age, 
fever, risk factors for HIV infection, rifabutin prophy- 
laxis, number of positive BCs, total and CD4 lympho- 
cyte count and platelet number. However, a correlation 
was established with weight loss, the presence of an 
AIDS-associated event, particularly CMV infection, 
cholestasis and severe anemia. 
In the multivariate analysis, only severe anemia was 
significantly associated with a poor prognosis, with an 
increased risk of death (relative risk of 2.28, 95% CI: 
1.15-4.49; p=0.02). 
DISCUSSION 
Our study, performed before the protease inhibitor era, 
underlines the fact that DMAC infection represents a 
major problem in HIV-infected patients with low CD4 
counts, despite nucleoside analogs and rifabutin 
prophylaxis. DMAC infection incidence was usually 
estimated as being between 15% and 24% [1,2,4] as in 
our study (18%). Our results confirm that the 
probability of detecting MAC in blood rises as the CD4 
count declines, since the median level in our study was 
4/mrn3, as previously described [2,5,6,11]. 
In our study, in a univariate analysis, several factors 
were revealed to be associated with a poorer prognosis, 
such as weight loss (or a decrease of Karnofsky score for 
others studies), and severe anemia (less than 9 g/dL or 
less than a hematocrit of 26%), as previously described 
[6,11-131, which might reflect BM involvement. 
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Table 2 Univariate analysis of factors associated with suMval in 52 HIV-infected patients with DMAC infection and CD4 
counts < i O O / m m 3  
SuMval in months 
Number of 
Mean Median patients P Variable 
HIV risk factor 
Homosexual 
Intravenous drug user 
Heterosexual 
Others' 
Prior opportunistic infection 
Yes 
No 
Fever (238°C) 
Yes 
No 
Weight lossb 
Yes 
No 
AIDS-associated eventC 
Yes 
No 
CMV-associated event 
Yes 
No 
Hemoglobin 
<9 g/dL 
2 9  g/dL 
Lymphocytes 
<400/mm3 
2400/mm3 
Platelet 
<loo 0 0 0 / ~ 3  
2 100 0 0 0 / ~ 3  
Cholestasisd 
Yes 
No 
Rifabutin prophylaxis 
Yes 
No 
MAC treatment 
Yes 
No 
7.64 
5.07 
6.00 
8.39 
6.00 
2.00 
4.50 
8.50 
34 
9 
3 
6 
0.68 
7.07 
7.61 
6.00 
5.00 
30 
22 
0.60 
0.37 
0.03 
0.003 
0.01 
0.02 
0.39 
0.25 
0.01 
0.25 
7.68 
5.67 
6.00 
4.00 
42 
10 
5.39 
9.52 
3.00 
8.40 
29 
. 23 
4.63 
9.83 
2.00 
8.40 
26 
26 
3.55 
8.24 
1.50 
7.00 
11 
41 
4.78 
8.83 
3.00 
7.00 
18 
34 
6.82 
8.62 
6.00 
6.29 
36 
15 
4.91 
6.97 
1 .oo 
6.74 
12 
38 
4.74 
9.08 
3.00 
7.00 
22 
30 
6.12 
8.16 
3.00 
7.75 
22 
30 
8.73 
2.00 
7.90 
- 
41 
11 4 0 - 4  
"Bisexual, transfusion. bWeight loss 25% in 2 months. CAIDS-associated event at the time of DMAC diagnosis or in the month following. 
dAlkaline phosphatases and y-glutamyltransferase 2 2  X upper limit of normal. CMV, cytomegalovirus. 
Eighteen patients with severe anemia died, with a 
median survival of 3 months (Table 2).  
Moreover, a slight increase in alkaline phosphatases 
is common (42%) and significantly associated with a 
shorter survival. However, the physiopathology of such 
an increase is unclear, since liver biopsies were not 
performed; it might be related to concomitant infec- 
tion due to CMV or other pathogens. Another study 
pointed out the high incidence of this abnormality and 
its prognostic value 1141. Severe lymphopenia or CD4 
depletion are not factors associated with a poor 
prognosis in our report, as they have been in others 
[6,11,12]. However, CD4 counts are so low in most 
patients that this variable may not be a good prognostic 
factor. 
Our study underlines the fact that DMAC infec- 
tion is often associated with another AIDS-related 
event (54%), particularly a CMV infection. A low CD4 
count may explain the multiplicity of AIDS events at 
this time. Hoover et al [15] estimated that the risk of 
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Table 3 
associated with survival in 52 HIV-infected patients with 
Dh4AC infection and CD4 count <100/mm3 
Multivariate analysis (Cox model) of factors 
Variable Relative risk (CI 95%) P 
Weight loss" - 0.27 
AIDS-associated eventb 1.89 (0.93-3.83) 0.08 
CMV-associated event - 0.79 
Cholestasis' 1.83 (0.90-3.76) 0.09 
Anemia (<9 g/dL.) 2.28 (1.15-4.49) 0.02 
"eight loss 25% in 2 months. bAIDS-associated event at the 
time of DMAC hagnosis or in the month following. <Alkaline 
phosphatases and y-glutamyltransferase 2 2  Xupper l imt  of normal. 
CMV, cytomegalovirus. 
developing DMAC infection is 2.65 higher in the case 
of a past record of CMV infection, while the risk of 
developing CMV infection is 3.96 higher in the case of 
a past record of DMAC infection. In another report, 
DMAC was the event that most increased the risk of 
developing CMV infection [16]. 
So, in the univariate analysis, another AIDS-related 
event, particularly a CMV infection, is clearly associ- 
ated with a shorter survival (p=0.003 and p=O.Ol 
respectively), as suggested by Chin et al [6] and Singer 
et a1 [13]. Another study underlined the fact that 
DMAC infection survival was shorter in the case of an 
association with CMV infection [17]. 
Antimycobacterial treatment is only partially 
effective, since 35 patients of 42 treated (83%) died 
during the follow-up. Median survival was 4 months, 
as described by others [5,6,11]. Treatments are not very 
effective, since the underlying immune deficiency and 
the associated opportunistic infections are devastating. 
In the univariate analysis, antimycobacterial treatment 
is associated with longer survival, as previously 
demonstrated [5,6,11]. Since the decision to treat 
patients with antimycobacterial drugs was not random- 
ized and the combination changed during the study, 
multivariate analysis was not performed for this co- 
variable, to avoid bias. However, in a prospective study, 
Chin et a1 161 showed that antimycobacterial therapy 
was independently associated with a lower risk of death. 
Unlike the level of mycobacteremia as noted by 
Horsburgh et a1 [l l] ,  the number of positive BCs was 
not associated with survival. In fact, this is a logical 
result because mycobacteremia may be transient, most- 
ly in early DMAC when the bacterial tissue burden is 
low and the prognosis better [18]. 
Finally, in a multivariate analysis, only severe 
anemia is significantly correlated with a shorter survival 
with an increased risk of death (relative risk of 2.28; 
95% confidence interval 1.15-4.49; p=0.02). For 
cholestasis and AIDS-associated events, there are only 
trends to significant results, which could be explained 
by the small number of patients studied. 
In conclusion, this prospective study among HIV- 
infected patients with CD4 counts <100/mm3 has 
shown that severe anemia is the most important factor 
associated with shorter survival. Cholestasis and an 
AIDS-associated event, particularly CMV infection, are 
also major prognostic factors, although not statistically 
significant in our study. With the development of more 
effective antiretroviral therapy, and particularly with the 
use of protease inhibitors, we noticed, as have others, a 
dramatic reduction of DMAC and CMV infection, 
both diseases which are present during the later stages 
of HIV infection. Therefore, our results underscore the 
importance of this strategy for DMAC control and thus 
improving survival in HIV infected patients. 
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Infections caused by coagulase-negative staphylococci 
(CNS) are commonly associated with implanted 
devices such as intravascular catheters, prosthetic heart 
valves and shunts [ 1,2]. Although several typing systems 
have helped to elucidate their epidemiology and mode 
of transmission, and to define outbreaks of nosocomial 
infections [3-6], little is known about the hospital 
epidemiology of CNS, including both methicdlin- 
resistant and methicillin-sensitive strains (MRCNS 
and MSCNS respectively). This is hrther complicated 
by the ubiquitous nature of CNS as human skin 
flora. CNS may also serve as a reservoir for antibiotic 
resistance genes that can be potentially transferred to 
other Gram-positive organisms, including Stuphylococcus 
aureus [7]. In order to better understand the epidemio- 
logy of antimicrobial resistance in CNS within the 
Heinrich-Heine University Hospital, Diisseldorf, routine 
susceptibility data for isolates derived from different 
body sites in patients from intensive care units (ICUs), 
regular wards and the bone marrow transplantation unit 
were reviewed. 
The Heinrich-Heine University Hospital Dussel- 
dorf is a 1500-bed hospital comprising regular care 
units and five units devoted to intensive medical care, 
namely the surgical ICU, pediatric ICU, neurologic 
ICU, internal medicine ICU and bone marrow trans- 
plant (BMT) unit. Between 1991 and 1996, all clinically 
significant CNS isolates &om blood cultures, catheter 
tips, liquors and aspirates, and all isolates &om immuno- 
compromised patients and other patients where CNS 
were suspected to be involved in a bacteremic episode, 
were referred for confirmation of identity and suscepti- 
bility testing. 
Isolates were identified as CNS by demonstra- 
ting a positive catalase test, a negative coagulase test 
(Bacto Coagulase Plasma EDTA-Test, Difco, Augsburg, 
